Understanding Treatment Preferences Among People Living with HIV in Australia: A Discrete Choice Experiment

References

• UNAids. Fact Sheet - World Aids Day. Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed March 17, 2022.
   Google Scholar
• Zwar N, Streeton CL. Pretravel advice and hepatitis A immunization among Australian travelers. J Travel Med. 2007;14(1):31–36. doi:10.1111/j.1708-8305.2006.00088.x
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Eng J Med. 2016;375(9):830–839. doi:10.1056/NEJMoa1600693
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. Aids. 2013;27(6):973–979. doi:10.1097/QAD.0b013e32835cae9c
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. EACS Guidelines Version 11.0 October 2021; 2021. Available from https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf. Accessed June 30, 2023.
   Google Scholar
• de Los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study. AIDS Behav. 2021;25(3):961–972. doi:10.1007/s10461-020-03055-1
   PubMed Web of Science ®Google Scholar
• Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting Cabotegravir + Rilpivirine for maintenance therapy: ALTAS week 48 results. Paper presented at: Conference of Retroviruses and Opportunistic Infections. 2019; Seattle, WA.
   Google Scholar
• Overton ET, Orkin C, Swindells S, et al. Monthly Long-Acting Cabotegravir and Rilpivirine is Noninferior to Oral ART as Maintenance Therapy for HIV-1 Infection: week 48 Pooled Analysis From the Phase 3 ATLAS and FLAIR Studies. Paper presented at: 10th IAS Conference on HIV Science. 2019; Mexico City, Mexico.
   Google Scholar
• Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2020;396(10267):1994–2005. doi:10.1016/S0140-6736(20)32666-0
   PubMed Web of Science ®Google Scholar
• Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020;382(12):1112–1123. doi:10.1056/NEJMoa1904398
   PubMed Web of Science ®Google Scholar
• Mühlbacher AC, Stoll M, Mahlich J, Nübling M. Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - A Discrete Choice Experiment. Health Econ Rev. 2013;3(1):30. doi:10.1186/2191-1991-3-30
   PubMedGoogle Scholar
• Bregigeon-Ronot S, Cheret A, Cabie A, et al. Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France. Patient Prefer Adherence. 2017;11:1159–1169. doi:10.2147/PPA.S130276
   PubMed Web of Science ®Google Scholar
• Hendriks A, Wijnen B, van Engelen R, et al. A best-worst scaling in Colombian patients to rank the characteristics of HIV/AIDS treatment. J Med Econ. 2018;21(5):468–473. doi:10.1080/13696998.2018.1440401
   PubMed Web of Science ®Google Scholar
• Simoni JM, Beima-Sofie K, Mohamed ZH, et al. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: a Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV. AIDS Patient Care STDS. 2019;33(3):104–111. doi:10.1089/apc.2018.0198
   PubMed Web of Science ®Google Scholar
• Hauber AB, Mohamed AF, Watson ME, Johnson FR, Hernandez JE. Benefits, risk, and uncertainty: preferences of antiretroviral-naive African Americans for HIV treatments. AIDS Patient Care STDS. 2009;23(1):29–34. doi:10.1089/apc.2008.0064
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Dziekan K, Flood E, Harding G, Jordan JC. Understanding patient preferences for HIV medications using adaptive conjoint analysis: feasibility assessment. Value Health. 2005;8(4):453–461. doi:10.1111/j.1524-4733.2005.00036.x
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Dziekan K, Schrader S, et al. Patient preferences among third agent HIV medications: a US and German perspective. AIDS Care. 2007;19(8):982–988. doi:10.1080/09540120701294278
   PubMed Web of Science ®Google Scholar
• Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808–816. doi:10.1097/00126334-200407010-00007
   PubMed Web of Science ®Google Scholar
• Muhlbacher AC, Stoll M, Mahlich J, Nubling M. Patient preferences for HIV/AIDS therapy - A discrete choice experiment. Health Econ Rev. 2013;3(1):14. doi:10.1186/2191-1991-3-14
   PubMedGoogle Scholar
• The PREFER Consortium. PREFER Recommendations - Why, when and how to assess and use patient preferences in medical product decision-making; 2022. Available from: https://zenodo.org/record/6491042#.YpQTXhNBz0p. Accessed June 30, 2023.
   Google Scholar
• Fifer S, Galinsky J, Richard S. Myeloma patient value mapping: a discrete choice experiment on myeloma treatment preferences in the UK. Patient Prefer Adherence. 2020;14:1283. doi:10.2147/PPA.S259612
   PubMed Web of Science ®Google Scholar
• Fifer S, Keen B, Newton R, Puig A, McGeachie M. Understanding the Treatment preferences of people living with Schizophrenia in Australia; a patient value mapping study. Patient Prefer Adherence. 2022;16:1687. doi:10.2147/PPA.S366522
   PubMed Web of Science ®Google Scholar
• McFadden DL. Conditional Logit Analysis of Qualitative Choice Analysis. New York Academic Press; 1974.
   Google Scholar
• Lancaster KJ. A new approach to consumer theory. J Political Eco. 1966;74(2):132–157. doi:10.1086/259131
   Google Scholar
• Louviere JJ, Hensher DA. On the design and analysis of simulated choice or allocation experiments in travel choice modelling. Transp Res Rec. 1982;890(1982):11–17.
   Google Scholar
• Louviere JJ, Woodworth G. Design and analysis of simulated consumer choice or allocation experiments: an approach based on aggregate data. J Marketing Res. 1983;20(4):350–367. doi:10.1177/002224378302000403
   Web of Science ®Google Scholar
• Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making. PharmacoEconomics. 2008;26(8):661–677. doi:10.2165/00019053-200826080-00004
   PubMed Web of Science ®Google Scholar
• Marshall D, Bridges JFP, Hauber B, et al. Conjoint analysis applications in health — how are studies being designed and reported? Patient Centered Outcomes Res. 2010;3(4):249–256. doi:10.2165/11539650-000000000-00000
   Web of Science ®Google Scholar
• Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. PharmacoEconomics. 2019;37(2):201–226. doi:10.1007/s40273-018-0734-2
   PubMed Web of Science ®Google Scholar
• Rizzardini G, Overton ET, Orkin C, et al. Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquired Immune Deficiency Syn. 2020;85(4):498. doi:10.1097/QAI.0000000000002466
   PubMed Web of Science ®Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Rose JM, Bliemer MCJ. Constructing efficient stated choice experimental designs. Transport Rev. 2009;29(5):587–617. doi:10.1080/01441640902827623
   Web of Science ®Google Scholar
• Brown G, Mikolajczak G, Lyons A, et al. Development and validation of PozQoL: a scale to assess quality of life of PLHIV. BMC Public Health. 2018;18(1):527. doi:10.1186/s12889-018-5433-6
   PubMedGoogle Scholar
• Gonzalez JM. A guide to measuring and interpreting attribute importance. Patient Patient Centered Outcomes Res. 2019;12(3):287–295. doi:10.1007/s40271-019-00360-3
   Web of Science ®Google Scholar
• Ostermann J, Muhlbacher A, Brown DS, et al. heterogeneous patient preferences for modern antiretroviral therapy: results of a discrete choice experiment. Value Health. 2020;23(7):851–861. doi:10.1016/j.jval.2020.03.007
   PubMed Web of Science ®Google Scholar
• Eaton EF, McDavid C, Banasiewicz MK, Mugavero MJ, Knight SJ. Patient preferences for antiretroviral therapy: effectiveness, quality of life, access and novel delivery methods. Patient Prefer Adherence. 2017;11:1585–1590. doi:10.2147/PPA.S142643
   PubMed Web of Science ®Google Scholar
• Philbin MM, Parish C, Bergen S, et al. A qualitative exploration of women’s interest in long-acting injectable antiretroviral therapy across six cities in the women’s interagency HIV study: intersections with current and past injectable medication and substance use. AIDS Patient Care STDS. 2021;35(1):23–30. doi:10.1089/apc.2020.0164
   PubMed Web of Science ®Google Scholar
• Jolayemi O, Bogart LM, Storholm ED, et al. Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: a qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS One. 2022;17(2):e0262926. doi:10.1371/journal.pone.0262926
   PubMed Web of Science ®Google Scholar